Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Trapidil after one year]

G B Agus1

  • 1Cattedra di Chirurgia Vascolare, Università degli Studi di Milano.

Minerva Cardioangiologica
|May 1, 1993
PubMed
Summary

Trapidil offers a versatile approach to treating arterio-vascular diseases by improving blood flow and reducing clotting. Clinical studies show Trapidil effectively manages intermittent claudication and rest pain in patients with peripheral artery disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial.

International angiology : a journal of the International Union of Angiology·2015
Same author

[Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].

Minerva cardioangiologica·2012
Same author

Effects of elastic compression on hypomobility edema and fibrinolysis activation in multiple sclerosis.

Panminerva medica·2011
Same author

[Medical treatment of chronic venous disease: evolution or involution?].

Minerva cardioangiologica·2011
Same author

Nautilus survey on chronic venous diseases.

Panminerva medica·2010
Same author

Risk of deep venous thrombosis (DVT) in bedridden or wheelchair-bound multiple sclerosis patients: a prospective study.

Thrombosis research·2009

Area of Science:

  • Pharmacology
  • Vascular Biology
  • Hemostasis

Context:

  • Cerebral limb ischemia requires a multifaceted pharmacological strategy addressing hydraulic, hemorheologic, and hemocoagulative factors.
  • Arterio-vascular diseases necessitate treatments that go beyond simple vasodilation.
  • Trapidil, a drug used in Italy for arterio-vascular diseases, has demonstrated significant therapeutic potential.

Purpose:

  • To evaluate the comprehensive pharmacological effects of Trapidil in managing arterio-vascular diseases.
  • To assess Trapidil's efficacy in improving hemorheologic properties and reducing thrombotic activity.
  • To present clinical evidence supporting Trapidil's therapeutic benefits in conditions like intermittent claudication.

Summary:

  • Trapidil exhibits superior antithrombocytic activity by inhibiting thromboxane A2 (TXA2) formation and promoting prostacyclin release.
  • It selectively inhibits platelet-derived growth factor (PDGF) mitogenic effects, preventing myointimal cell proliferation.
  • Experimental models suggest Trapidil enhances blood hemorheologic properties.
  • Clinical studies, including a polycentric trial on 200 patients with stage II and III arterio-occlusive peripheral disease (AOCP), demonstrate Trapidil's effectiveness in improving walking distance and reducing pain.

Impact:

  • Trapidil provides a novel therapeutic option for arterio-vascular diseases, addressing multiple pathophysiological aspects.
  • Its dual action on thrombosis and vascular cell proliferation offers a comprehensive treatment strategy.
  • Clinical validation supports Trapidil's use in managing symptoms of peripheral artery disease, enhancing patient quality of life.

Related Experiment Videos